Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-795

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 795 26 Master Bottle Label Approval Rev A 01 22)

Label for Losartan Potassium Tablets, USP 50 mg, containing 90 tablets in a bottle. The label indicates prescription use only with storage instructions at controlled room temperature and protection from light. Manufactured by Northwind Pharmaceuticals and repackaged by Northwind Health Company, LLC.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over 66 study months for Atenolol and Losartan Potassium. The graph includes an annotation highlighting a 13% adjusted risk reduction with Losartan Potassium, with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Atenolol and Losartan Potassium. The graph shows cumulative risk over time, with Losartan Potassium demonstrating lower stroke incidence. The chart includes an annotation of adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure displaying forest plots comparing the primary composite endpoint and stroke events between Losartan Potassium and Atenolol across various demographic subgroups, including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The plots show event rates and hazard ratios with confidence intervals, illustrating which treatment favors better outcomes.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph showing the percentage of patients with events over a period of up to 48 months. It compares Losartan Potassium (solid line) with Placebo (dashed line), indicating a risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, illustrating the molecular arrangement of atoms, including nitrogen, chlorine, oxygen, potassium, and carbon groups forming the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.